scispace - formally typeset
P

Peter Cassiman

Publications -  5
Citations -  506

Peter Cassiman is an academic researcher. The author has contributed to research in topics: Anemia of chronic disease & Red blood cell. The author has an hindex of 4, co-authored 5 publications receiving 468 citations.

Papers
More filters
Journal ArticleDOI

Telomere length and cardiovascular risk factors in a middle‐aged population free of overt cardiovascular disease

TL;DR: It is shown that TL of peripheral blood leukocytes primarily reflects the burden of increased oxidative stress and inflammation, whether or not determined by an increasingly unhealthy lifestyle, while the association with classical CVD risk factors is limited.
Journal ArticleDOI

Rationale, design, methods and baseline characteristics of the Asklepios Study.

TL;DR: The Asklepios Study is a longitudinal population study focusing on the interplay between ageing, cardiovascular haemodynamics and inflammation in (preclinical) cardiovascular disease, and the systematic determination of peripheral blood leukocyte telomere length as a marker for biological ageing.
Journal ArticleDOI

Lower red blood cell counts in middle‐aged subjects with shorter peripheral blood leukocyte telomere length

TL;DR: It is suggested that critical telomere shortening might also limit erythropoiesis in vivo, while negligible in a middle‐aged population, the clinical consequences might be important in the elderly (e.g. in anemia of chronic disease).
Journal Article

Anticonceptive drug use and increased carotid and femoral plaque prevalence: Population data from asklepios

TL;DR: Use of contraceptive therapy is very common and associated with an unexpected increase in the prevalence of carotid and femoral atherosclerosis in otherwise young, apparently healthy women, and OC use could be an important factor in the global atherosclerotic burden.
Journal ArticleDOI

Abstract 3614: Anticonceptive Drug Use And Increased Carotid and Femoral Plaque Prevalence: Population Data From Asklepios

TL;DR: Combination therapy with the female hormones estrogen (E) and progestins are very frequently used with approximately 100 million women worldwide taking oral contraceptives (OC) as mentioned in this paper, with approximately 80% taking OTC.